ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Nikhil Lalwani Sells 1,318 Shares

ANI Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Nikhil Lalwani sold 1,318 ANI Pharmaceuticals shares at an average $71.40, totaling $94,105.20. The sale was made under a pre-arranged Rule 10b5-1 plan; he retained 332,371 shares.
  • ANI reported quarterly EPS of $2.70, beating estimates of $2.18, while revenue rose 27.6% year over year to $290.78 million.
  • Analysts’ consensus rating is Hold, with an average price target of $100; shares recently traded at $71.47.
  • MarketBeat previews the top five stocks to own by December 1st.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 1,318 shares of the company's stock in a transaction on Monday, November 16th. The stock was sold at an average price of $71.40, for a total transaction of $94,105.20. Following the completion of the sale, the chief executive officer owned 332,371 shares of the company's stock, valued at $23,731,289.40. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

  • On Wednesday, November 18th, Nikhil Lalwani sold 4,082 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $71.16, for a total value of $290,475.12.
  • On Thursday, October 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $71.89, for a total value of $388,206.00.
  • On Tuesday, September 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.00, for a total value of $383,400.00.
  • On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.30, for a total value of $401,220.00.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded up $1.48 during trading hours on Wednesday, reaching $71.47. 314,389 shares of the company were exchanged, compared to its average volume of 501,263. ANI Pharmaceuticals, Inc. has a 12 month low of $67.14 and a 12 month high of $87.76. The company has a current ratio of 2.75, a quick ratio of 2.33 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average of $72.32 and a 200 day moving average of $76.85. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of 14.24, a PEG ratio of 2.19 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a net margin of 11.22% and a return on equity of 28.34%. The company had revenue of $290.78 million for the quarter, compared to analyst estimates of $280.59 million. During the same quarter last year, the firm posted $2.04 earnings per share. The company's quarterly revenue was up 27.6% compared to the same quarter last year. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals in the first quarter worth $28,000. Versant Capital Management Inc increased its position in ANI Pharmaceuticals by 103.3% during the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company's stock worth $31,000 after acquiring an additional 217 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in ANI Pharmaceuticals during the 3rd quarter valued at $32,000. USA Financial Formulas acquired a new position in ANI Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Sterling Capital Management LLC raised its stake in ANI Pharmaceuticals by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company's stock valued at $50,000 after purchasing an additional 612 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Weiss Ratings reiterated a "hold (c+)" rating on shares of ANI Pharmaceuticals in a report on Wednesday, November 4th. Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 target price for the company. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $119.00 to $121.00 and gave the company a "buy" rating in a report on Friday, November 6th. Canaccord Genuity Group lowered their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Finally, Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $100.00.

Get Our Latest Analysis on ANIP

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company's rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

See Also

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ANI Pharmaceuticals Right Now?

Before you consider ANI Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.

While ANI Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines